Proteins involved in extracellular matrix dynamics are associated with respiratory syncytial virus disease severity

European Respiratory Journal

Volumn 39, Issue 6, 2012, Pages 1475-1481

  Schuurhof, Annemieke ^a,b   Bont, Louis ^b   Hodemaekers, Hennie M ^a   De Klerk, Arja ^a   De Groot, Hanneke ^a,b   Hofland, Regina W ^b   Van De Pol, Alma C ^b   Kimpen, Jan L L ^b   Janssen, Riny ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bronchiolitis; Genetic polymorphism; Matrix metalloproteinase 3; Tissue inhibitor of metalloproteinases 1

Indexed keywords

DNA; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; ARTIFICIAL VENTILATION; BRONCHIOLITIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; EXTRACELLULAR MATRIX; FEMALE; HOSPITAL PATIENT; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; NASOPHARYNGEAL ASPIRATION; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SCREENING TEST;

ACUTE DISEASE; BIOLOGICAL MARKERS; BRONCHIOLITIS; COHORT STUDIES; EXTRACELLULAR MATRIX; FEMALE; GENETIC VARIATION; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 3; RESPIRATION, ARTIFICIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84861872235     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00012311     Document Type: Article

References (31)

1. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282: 1440-1446.
2. McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull 2002; 61: 13-28.
3. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137: 865-870.
4. Bont L, van Vught AJ, Kimpen JL. Prophylaxis against respiratory syncytial virus in premature infants. Lancet 1999; 354: 1003-1004.
5. Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354: 847-852.
6. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 2007; 120: e1076-e1081.
7. Houben ML, Coenjaerts FE, Rossen JW, et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 2010; 82: 1266-1271.
8. van de Pol AC, Wolfs TF, van Loon AM, et al. Molecular quantification of respiratory syncytial virus in respiratory samples: reliable detection during the initial phase of infection. J Clin Microbiol 2010; 48: 3569-3574.
9. Bont L, Heijnen CJ, Kavelaars A, et al. Local interferon-γ levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 2001; 184: 355-358.
10. Janssen R, Bont L, Siezen CL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 2007; 196: 826-834.
11. Schuurhof A, Bont L, Siezen CL, et al. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Pediatr Pulmonol 2010; 45: 608-613.
12. Siezen CL, Bont L, Hodemaekers HM, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J 2009; 28: 333-335.
13. Viet AL, van den Hof S, Elvers LH, et al. Risk factors and health in the Netherlands, a survey by municipal public; annual report 2001. RIVM report 260854004. Bilthoven, National Institute for Public Health and the Environment, 2003.
14. Hoebee B, Rietveld E, Bont L, et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor α polymorphisms. J Infect Dis 2003; 187: 2-11.
15. Bemjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testin. J R Stat Soc B 1995; 57: 289-300.
16. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540-551.
17. Goyette J, Yan WX, Yamen E, et al. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol 2009; 183: 593-603.
18. Elliott MB, Welliver RC Sr, Laughlin TS, et al. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infection. J Med Virol 2007; 79: 447-456.
19. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007; 87: 69-98.
20. Gueders MM, Foidart JM, Noel A, et al. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006; 533: 133-144.
21. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-464.
22. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by Gram-negative bacteria and in septic shock. Clin Microbiol Rev 2009; 22: 224-239.
23. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-3727.
24. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
25. Hoffmann U, Bertsch T, Dvortsak E, et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006; 38: 867-872.
26. Lee MM, Yoon BJ, Osiewicz K, et al. Tissue inhibitor of metalloproteinase 1 regulates resistance to infection. Infect Immun 2005; 73: 661-665.
27. Yeo SJ, Yun YJ, Lyu MA, et al. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol 2002; 147: 229-242.
28. Nerusu KC, Warner RL, Bhagavathula N, et al. Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. Exp Mol Pathol 2007; 83: 169-176.
29. Davies PL, Spiller OB, Beeton ML, et al. Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax 2010; 65: 246-251.
30. Tasker RC, Roe MF, Bloxham DM, et al. The neuroendocrine stress response and severity of acute respiratory syncytial virus bronchiolitis in infancy. Intensive Care Med 2004; 30: 2257-2262.
31. McNamara PS, Flanagan BF, Hart CA, et al. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2005; 191: 1225-1232.